Mary-Kate Malecek, June K Robinson, Karl Bilimoria, Jennifer N Choi, Jaehyuk Choi, Pedram Gerami, Timothy Kruser, Timothy Kuzel, Mary Martini, Jonathan B Strauss, Jeffrey Wayne, Jeffrey Sosman, Sunandana Chandra
{"title":"不可切除黑色素瘤的进展:多学科视角。","authors":"Mary-Kate Malecek, June K Robinson, Karl Bilimoria, Jennifer N Choi, Jaehyuk Choi, Pedram Gerami, Timothy Kruser, Timothy Kuzel, Mary Martini, Jonathan B Strauss, Jeffrey Wayne, Jeffrey Sosman, Sunandana Chandra","doi":"10.2217/mmt-2016-0003","DOIUrl":null,"url":null,"abstract":"chemotherapy with alkylating agents as dacarbazine temozolomide. to reported in clinical trials Other alkylating agents and combination regimens of cytotoxic chemotherapy or biotherapy with inter-feron failed to show significant improvement in overall survival.","PeriodicalId":44562,"journal":{"name":"Melanoma Management","volume":"3 3","pages":"171-175"},"PeriodicalIF":1.0000,"publicationDate":"2016-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2217/mmt-2016-0003","citationCount":"0","resultStr":"{\"title\":\"Advancements in unresectable melanoma: a multidisciplinary perspective.\",\"authors\":\"Mary-Kate Malecek, June K Robinson, Karl Bilimoria, Jennifer N Choi, Jaehyuk Choi, Pedram Gerami, Timothy Kruser, Timothy Kuzel, Mary Martini, Jonathan B Strauss, Jeffrey Wayne, Jeffrey Sosman, Sunandana Chandra\",\"doi\":\"10.2217/mmt-2016-0003\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"chemotherapy with alkylating agents as dacarbazine temozolomide. to reported in clinical trials Other alkylating agents and combination regimens of cytotoxic chemotherapy or biotherapy with inter-feron failed to show significant improvement in overall survival.\",\"PeriodicalId\":44562,\"journal\":{\"name\":\"Melanoma Management\",\"volume\":\"3 3\",\"pages\":\"171-175\"},\"PeriodicalIF\":1.0000,\"publicationDate\":\"2016-09-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.2217/mmt-2016-0003\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Melanoma Management\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.2217/mmt-2016-0003\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2016/8/16 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q4\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Melanoma Management","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2217/mmt-2016-0003","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2016/8/16 0:00:00","PubModel":"Epub","JCR":"Q4","JCRName":"ONCOLOGY","Score":null,"Total":0}
Advancements in unresectable melanoma: a multidisciplinary perspective.
chemotherapy with alkylating agents as dacarbazine temozolomide. to reported in clinical trials Other alkylating agents and combination regimens of cytotoxic chemotherapy or biotherapy with inter-feron failed to show significant improvement in overall survival.
期刊介绍:
Skin cancer is on the rise. According to the World Health Organization, 132,000 melanoma skin cancers occur globally each year. While early-stage melanoma is usually relatively easy to treat, once disease spreads prognosis worsens considerably. Therefore, research into combating advanced-stage melanoma is a high priority. New and emerging therapies, such as monoclonal antibodies, B-RAF and KIT inhibitors, antiangiogenic agents and novel chemotherapy approaches hold promise for prolonging survival, but the search for a cure is ongoing. Melanoma Management publishes high-quality peer-reviewed articles on all aspects of melanoma, from prevention to diagnosis and from treatment of early-stage disease to late-stage melanoma and metastasis. The journal presents the latest research findings in melanoma research and treatment, together with authoritative reviews, cutting-edge editorials and perspectives that highlight hot topics and controversy in the field. Independent drug evaluations assess newly approved medications and their role in clinical practice. Key topics covered include: Risk factors, prevention and sun safety education Diagnosis, staging and grading Surgical excision of melanoma lesions Sentinel lymph node biopsy Biological therapies, including immunotherapy and vaccination Novel chemotherapy options Treatment of metastasis Prevention of recurrence Patient care and quality of life.